BrainsWay Ltd. (NASDAQ:BWAY) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP grew its holdings in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 32.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 60,600 shares of the company’s stock after acquiring an additional 14,900 shares during the quarter. Two Sigma Advisers LP owned about 0.32% of BrainsWay worth $571,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Lazard Asset Management LLC acquired a new position in BrainsWay during the 4th quarter worth $44,000. Sei Investments Co. acquired a new position in BrainsWay during the 4th quarter worth $149,000. Cubist Systematic Strategies LLC boosted its position in BrainsWay by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after acquiring an additional 2,446 shares during the period. Rhumbline Advisers boosted its position in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after acquiring an additional 2,144 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in BrainsWay by 61.9% during the 4th quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after acquiring an additional 9,149 shares during the period. Institutional investors and hedge funds own 30.11% of the company’s stock.

BrainsWay Stock Down 0.3%

Shares of BrainsWay stock opened at $10.19 on Wednesday. The firm has a market cap of $192.31 million, a price-to-earnings ratio of 101.91 and a beta of 1.25. The business has a fifty day simple moving average of $9.26 and a 200-day simple moving average of $9.74. BrainsWay Ltd. has a fifty-two week low of $5.67 and a fifty-two week high of $11.79.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The business had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. Analysts anticipate that BrainsWay Ltd. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.